The portal immunosuppressive storm - Relevance to islet transplantation?

被引:102
|
作者
Shapiro, AMJ
Gallant, HL
Hao, EG
Lakey, JRT
McCready, T
Rajotte, RV
Yatscoff, RW
Kneteman, NM
机构
[1] Univ Alberta, Dept Surg, Edmonton, AB, Canada
[2] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada
[3] Isotech Inc, Edmonton, AB, Canada
关键词
irrummosuppression; islet; sirolimus; tacrolimus; transplantation;
D O I
10.1097/00007691-200502000-00008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Outcomes in clinical islet transplantation improved substantially with the introduction of combined sirolimus and tacrolimus immunosuppression. However, multiple islet preparations are often required to achieve insulin independence, suggesting that islet engraftment may not be optimal when these agents are absorbed via the portal vein. The current study was designed to assess the differential concentrations of immunosuppressive drugs within the portal and systemic circulations of a large animal model, to assess the local concentrations of drugs to which islets are exposed early after implantation. Chronic catheters were placed in the portal vein and carotid artery of 6 mongrel dogs, and immunosuppressants were administered orally. Blood samples were drawn simultaneously from portal and systemic catheters, and drug concentrations were analyzed. Peak immunosuppressant levels as well as area under the curve were dramatically elevated in portal blood relative to systemic levels for all drugs tested. This "portal storm" of immunosuppression may be relevant to intrahepatic islet transplantation.
引用
收藏
页码:35 / 37
页数:3
相关论文
共 50 条
  • [1] Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation
    Roelen, D. L.
    Huurman, V. A. L.
    Hilbrands, R.
    Gillard, P.
    Duinkerken, G.
    van der Meer-Prins, P. W. M.
    Maarschalk, M. F. J. Versteeg-Van der Voort
    Mathieu, C.
    Keymeulen, B.
    Pipeleers, D. G.
    Roep, B. O.
    Claas, F. H. J.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 156 (01) : 141 - 148
  • [2] Immunology of pancreatic islet transplantation
    Reffet, S.
    Thivolet, C.
    DIABETES & METABOLISM, 2006, 32 (05) : 523 - 526
  • [3] Minimization of immunosuppressive therapy after islet transplantation: Combined action of heme oxygenase-1 and PEGylation to islet
    Lee, D. Y.
    Lee, S.
    Nam, J. H.
    Byun, Y.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (08) : 1820 - 1828
  • [4] Influence of hepatic cells on allogeneic islet transplantation in rats without immunosuppressive drugs
    Jara-Albarrán, A
    Soto-Montenegro, L
    del Rio, R
    Alvarez, S
    Martin-Scapa, C
    HORMONE AND METABOLIC RESEARCH, 2001, 33 (01) : 30 - 33
  • [5] Immunosuppressive Therapy in Transplantation
    Allison, Terri L.
    NURSING CLINICS OF NORTH AMERICA, 2016, 51 (01) : 107 - +
  • [6] Pancreatic islet transplantation
    Johnson, Paul R. V.
    Jones, Katherine E.
    SEMINARS IN PEDIATRIC SURGERY, 2012, 21 (03) : 272 - 280
  • [7] Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of rapamycin to enhance allogeneic islet graft viability
    Burke, Jacqueline A.
    Zhang, Xiaomin
    Bobbala, Sharan
    Frey, Molly A.
    Fuentes, Carolina Bohorquez
    Haddad, Helena Freire
    Allen, Sean D.
    Richardson, Reese A. K.
    Ameer, Guillermo A.
    Scott, Evan A.
    NATURE NANOTECHNOLOGY, 2022, 17 (03) : 319 - +
  • [8] Immunosuppressive therapy after transplantation
    Hofbauer, G.
    HAUTARZT, 2010, 61 (03): : 214 - 219
  • [9] PANCREAS AND ISLET TRANSPLANTATION IN MAN
    TIMSIT, J
    LEGENDRE, C
    CHATENOUD, L
    BOITARD, C
    BIOMEDICINE & PHARMACOTHERAPY, 1992, 46 (2-3) : 71 - 78
  • [10] Current challenges in islet transplantation
    Cristiane B. Leitão
    Pablo Cure
    Thipaporn Tharavanij
    David A. Baidal
    Rodolfo Alejandro
    Current Diabetes Reports, 2008, 8